Genflow Biosciences: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Genflow Biosciences
Largest movements
- Intangible fixed assets +€1.1m
up €1.1m (+89.3%), from €1.3m to €2.4m
- Deferred charges and accrued income +€564,243
up €564,243 (+142%), from €398,559 to €962,802
- Cash -€191,223
down €191,223 (-87.6%), from €218,305 to €27,082
mainly Investment in fixed assets (net) (-€1.1m) and Deferred charges and accrued income (-€564,243)
- Other debts +€1.1m
up €1.1m (+115%), from €959,775 to €2.1m
- Investment grants +€562,261
up €562,261 (+142%), from €396,384 to €958,645
- Profit (loss) carried forward -€267,933
down €267,933 (-39.4%), from -€680,627 to -€948,560
- Trade debts +€91,285
up €91,285 (+13.8%), from €659,600 to €750,884
- Gross operating margin +€18,188
up €18,188 (+6.4%), from -€282,434 to -€264,246
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,238,505 | €3,736,799 | +€1.5m | +66.9% |
| Fixed assets | 21/28 | €1,282,769 | €2,424,400 | +€1.1m | +89.0% |
| Intangible fixed assets | 21 | €1,280,271 | €2,423,175 | +€1.1m | +89.3% |
| Tangible fixed assets | 22/27 | €2,499 | €1,225 | -€1,274 | -51.0% |
| Furniture and vehicles | 24 | €2,499 | €1,225 | -€1,274 | -51.0% |
| Current assets | 29/58 | €955,736 | €1,312,399 | +€356,663 | +37.3% |
| Amounts receivable within one year | 40/41 | €338,872 | €322,515 | -€16,357 | -4.8% |
| Trade receivables | 40 | €300,793 | €298,730 | -€2,064 | -0.7% |
| Other amounts receivable | 41 | €38,079 | €23,785 | -€14,293 | -37.5% |
| Cash at bank and in hand | 54/58 | €218,305 | €27,082 | -€191,223 | -87.6% |
| Deferred charges and accrued income | 490/1 | €398,559 | €962,802 | +€564,243 | +142% |
| Total equity and liabilities | 10/49 | €2,238,505 | €3,736,799 | +€1.5m | +66.9% |
| Equity | 10/15 | €602,186 | €896,515 | +€294,329 | +48.9% |
| Contributions | 10/11 | €886,430 | €886,430 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€680,627 | -€948,560 | -€267,933 | -39.4% |
| Investment grants | 15 | €396,384 | €958,645 | +€562,261 | +142% |
| Amounts payable | 17/49 | €1,636,319 | €2,840,284 | +€1.2m | +73.6% |
| Amounts payable within one year | 42/48 | €1,636,319 | €2,840,284 | +€1.2m | +73.6% |
| Financial debts | 43 | €144 | €6,241 | +€6,097 | +4,233% |
| Credit institutions | 430/8 | €144 | €6,241 | +€6,097 | +4,233% |
| Trade debts | 44 | €659,600 | €750,884 | +€91,285 | +13.8% |
| Suppliers | 440/4 | €659,600 | €750,884 | +€91,285 | +13.8% |
| Taxes, remuneration and social security | 45 | €16,800 | €20,030 | +€3,230 | +19.2% |
| Taxes | 450/3 | €10,200 | €20,030 | +€9,830 | +96.4% |
| Remuneration and social security | 454/9 | €6,600 | €0 | -€6,600 | -100% |
| Other amounts payable | 47/48 | €959,775 | €2,063,128 | +€1.1m | +115% |
| Non-recurring operating income | 76A | €9,199 | €0 | -€9,199 | -100% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,418 | €1,294 | -€124 | -8.7% |
| Other operating charges | 640/8 | €1,050 | €2,071 | +€1,021 | +97.2% |
| Non-recurring operating charges | 66A | €35,902 | €156 | -€35,746 | -99.6% |
| Gross operating margin | 9900 | -€282,434 | -€264,246 | +€18,188 | +6.4% |
| Operating profit (loss) | 9901 | -€320,804 | -€267,767 | +€53,037 | +16.5% |
| Financial income | 75/76B | €1 | €1,519 | +€1,518 | +124,390% |
| Recurring financial income | 75 | €1 | €1,519 | +€1,518 | +124,390% |
| Financial charges | 65/66B | €3,772 | €1,684 | -€2,088 | -55.4% |
| Recurring financial charges | 65 | €3,772 | €1,684 | -€2,088 | -55.4% |
| Profit (loss) for the period before taxes | 9903 | -€324,575 | -€267,933 | +€56,642 | +17.5% |
| Profit (loss) for the period | 9904 | -€324,575 | -€267,933 | +€56,642 | +17.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€324,575 | -€267,933 | +€56,642 | +17.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 20 October 2026 via checked.be.